Logo image of TARA

PROTARA THERAPEUTIC INC (TARA) Stock Price, Quote, News and Overview

NASDAQ:TARA - Nasdaq - US74365U1079 - Common Stock - Currency: USD

3.5  +0.1 (+2.94%)

After market: 3.5 0 (0%)

TARA Quote, Performance and Key Statistics

PROTARA THERAPEUTIC INC

NASDAQ:TARA (4/30/2025, 8:00:01 PM)

After market: 3.5 0 (0%)

3.5

+0.1 (+2.94%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High10.48
52 Week Low1.6
Market Cap128.69M
Shares36.77M
Float35.39M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-01 2025-05-01
IPO10-22 2014-10-22


TARA short term performance overview.The bars show the price performance of TARA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40

TARA long term performance overview.The bars show the price performance of TARA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 5 10 15 20

The current stock price of TARA is 3.5 USD. In the past month the price decreased by -12.72%. In the past year, price increased by 20.27%.

PROTARA THERAPEUTIC INC / TARA Daily stock chart

TARA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19 345.13B
AMGN AMGEN INC 14.68 156.41B
GILD GILEAD SCIENCES INC 13.76 132.82B
VRTX VERTEX PHARMACEUTICALS INC 1756.9 130.98B
REGN REGENERON PHARMACEUTICALS 13.51 65.46B
ARGX ARGENX SE - ADR 339.55 39.39B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 34.24B
ONC BEIGENE LTD-ADR N/A 28.00B
BNTX BIONTECH SE-ADR N/A 25.04B
NTRA NATERA INC N/A 20.40B
SMMT SUMMIT THERAPEUTICS INC N/A 17.79B
BIIB BIOGEN INC 7.35 17.72B

About TARA

Company Profile

TARA logo image Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. The company is headquartered in New York City, New York and currently employs 28 full-time employees. The company went IPO on 2014-10-22. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The firm is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.

Company Info

PROTARA THERAPEUTIC INC

345 Park Avenue South, 3rd Floor

New York City NEW YORK 10010 US

CEO: Jesse Shefferman

Employees: 27

Company Website: https://protaratx.com/

Investor Relations: https://ir.protaratx.com/investor-overview

Phone: 16468440337

PROTARA THERAPEUTIC INC / TARA FAQ

What is the stock price of PROTARA THERAPEUTIC INC today?

The current stock price of TARA is 3.5 USD. The price increased by 2.94% in the last trading session.


What is the ticker symbol for PROTARA THERAPEUTIC INC stock?

The exchange symbol of PROTARA THERAPEUTIC INC is TARA and it is listed on the Nasdaq exchange.


On which exchange is TARA stock listed?

TARA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for PROTARA THERAPEUTIC INC stock?

11 analysts have analysed TARA and the average price target is 25.5 USD. This implies a price increase of 628.57% is expected in the next year compared to the current price of 3.5. Check the PROTARA THERAPEUTIC INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PROTARA THERAPEUTIC INC worth?

PROTARA THERAPEUTIC INC (TARA) has a market capitalization of 128.69M USD. This makes TARA a Micro Cap stock.


How many employees does PROTARA THERAPEUTIC INC have?

PROTARA THERAPEUTIC INC (TARA) currently has 27 employees.


What are the support and resistance levels for PROTARA THERAPEUTIC INC (TARA) stock?

PROTARA THERAPEUTIC INC (TARA) has a support level at 3.35 and a resistance level at 4.24. Check the full technical report for a detailed analysis of TARA support and resistance levels.


Should I buy PROTARA THERAPEUTIC INC (TARA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PROTARA THERAPEUTIC INC (TARA) stock pay dividends?

TARA does not pay a dividend.


When does PROTARA THERAPEUTIC INC (TARA) report earnings?

PROTARA THERAPEUTIC INC (TARA) will report earnings on 2025-05-01.


What is the Price/Earnings (PE) ratio of PROTARA THERAPEUTIC INC (TARA)?

PROTARA THERAPEUTIC INC (TARA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.41).


What is the Short Interest ratio of PROTARA THERAPEUTIC INC (TARA) stock?

The outstanding short interest for PROTARA THERAPEUTIC INC (TARA) is 5.73% of its float. Check the ownership tab for more information on the TARA short interest.


TARA Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to TARA. When comparing the yearly performance of all stocks, TARA turns out to be only a medium performer in the overall market: it outperformed 44.32% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

TARA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to TARA. No worries on liquidiy or solvency for TARA as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TARA Financial Highlights

Over the last trailing twelve months TARA reported a non-GAAP Earnings per Share(EPS) of -2.41. The EPS increased by 32.49% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -24.58%
ROE -26.68%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%45.56%
Sales Q2Q%N/A
EPS 1Y (TTM)32.49%
Revenue 1Y (TTM)N/A

TARA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to TARA. The Buy consensus is the average rating of analysts ratings from 11 analysts.


Ownership
Inst Owners85.9%
Ins Owners3.82%
Short Float %5.73%
Short Ratio5.68
Analysts
Analysts83.64
Price Target25.5 (628.57%)
EPS Next Y26.27%
Revenue Next YearN/A